Analysis of Harvest Moon's corporate history, corporate relationships, biosimilars development pipeline, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.
Description
INTRODUCTION
This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.
FEATURES AND BENEFITS
Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.
HIGHLIGHTS
Harvest Moon specializes in the development of complex generics and biosimilars. These products are in-licensed from emerging market copy-biologic developers before they are out-licensed to partners in developed markets, with Harvest Moon's receiving royalties. Harvest Moon has 30 biosimilar products in various stages of development.
YOUR KEY QUESTIONS ANSWERED
See how Harvest Moon relies on corporate relationships for both sourcing products and commercialization
Evaluate key products in Harvest Moon's pipeline, which is one of the largest monoclonal antibody biosimilar pipelines globally
Table of Contents
Table of Contents
ABOUT THIS REPORT
Chapter structure
Strategic insight
Product analysis
Operating performance
Company introduction
Data sourcing
PharmaVitae Explorer database
EXECUTIVE SUMMARY
Harvest Moon biosimilars SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
STRATEGIC INSIGHT
Harvest Moon plans to use simple biologic products to gain market experience
Harvest Moon operates a virtual biotech model
Low-cost products can be sourced from China and Taiwan
Sales agreements facilitate market entry
Phase I trials offered as optional add-on
Products can be launched in emerging markets while waiting for mature market access
KEY PRODUCTS
Overview
Harvest Moon biosimilar portfolio
Human insulin
Overview
Human insulin market size
Key competitors
Insulin glargine and lispro
Overview
Insulin glargine and lispro market size
Key competitors
Erythropoietin
Overview
Erythropoietin market size
Key competitors
Filgrastim and pegfilgrastim
Overview
Filgrastim and pegfilgrastim market size
Key competitors
Etanercept
Overview
Etanercept market size
Key competitors
Imiglucerase
Overview
Imiglucerase market size
Key competitors
Interferon beta-1a and -1b
Overview
Interferon beta market size
Key competitors
Other products
CORPORATE STRUCTURE
Background
Deals and alliances
Recent developments
APPENDIX
References
Datamonitor reports
Exchange rates
TABLES
Table: Harvest Moon - biosimilar portfolio
Table: Forecasted human insulin sales in the seven major markets ($m), 2011-16
Table: Biosimilar human insulin, products currently launched or in development
Table: Forecasted lispro and glargine insulin sales ($m), 2011-16
Table: Biosimilar human insulin, insulin glargine, and insulin lispro products currently launched or in development
Table: Forecasted epoetin and darbepoetin sales ($m), 2011-16
Table: Harvest Moon - pipeline and marketed biosimilar epoetin drugs
Table: Forecasted filgrastim and pegfilgrastim sales ($m), 2011-16
Table: Harvest Moon - pipeline and marketed biosimilar filgrastim and pegfilgrastim drugs
Table: Harvest Moon's other products/candidates in unknown stages of development
Table: Exchange rates, 2011
FIGURES
Figure: The PharmaVitae Explorer
Figure: Harvest Moon SWOT analysis
Figure: Harvest Moon's partnership and licensee strategy
Harvest Moon Pharmaceuticals: Biosimilars Company Analysis published by Datamonitor in July 6, 2012. This report consists of Pages: 35 and the price starts from US $ 3800.
